MOTS-c is a small peptide that your mitochondria make on their own. It was discovered in 2015. In mice it reduced diet-induced obesity and insulin resistance, and in later work it improved physical capacity in old animals. People also make it: exercise raises MOTS-c in human muscle and blood.
What is still missing is proof that taking MOTS-c helps people:
No FDA-approved MOTS-c drug exists.
The first placebo-controlled trial of MOTS-c itself is still recruiting. It is a Phase 2a study in adults with prediabetes, with primary completion estimated for February 2027.
A related analog, CB4211, finished an early safety study in 2021. No results are posted on ClinicalTrials.gov.
On October 30, 2026, HHS added MOTS-c to an interim policy that lets licensed pharmacies compound it for individual prescriptions under strict conditions. That is enforcement discretion, not approval.
This PeptIQ.io guide was rewritten on November 5, 2026 from the original papers, ClinicalTrials.gov and FDA and HHS documents. It contains no dosing information.
Talk to a licensed clinician before using MOTS-c or any product sold as MOTS-c.
What Is MOTS-c?
MOTS-c stands for "mitochondrial open reading frame of the 12S rRNA type-c." The name describes where it comes from. Mitochondria, the structures that make most of a cell's energy, have their own small genome. Researchers at the University of Southern California found a short stretch inside one mitochondrial gene, the one for 12S ribosomal RNA, that codes for a 16-amino-acid peptide. They described it in Cell Metabolism in 2015.
That made MOTS-c one of a small family called mitochondrial-derived peptides, along with humanin. These peptides suggest mitochondria do more than make energy. They may also send signals to the rest of the body.
Other spellings you will see: MOTSc, MOTs-C and MOTS-C. They all refer to the same peptide. The compounded form in the HHS policy is MOTS-c acetate, a salt form of the same sequence.
PeptIQ.io / MOTS-c / 01
A peptide made by mitochondria.
Most proteins are encoded in the cell nucleus. MOTS-c is one of a few peptides encoded in the mitochondria's own small genome.
1
Source
Mitochondrial DNA
A short open reading frame inside the gene for 12S ribosomal RNA.
2
Product
16 amino acids
A small peptide that can leave the cell and circulate in blood.
3
Main target
Skeletal muscle
The tissue the 2015 discovery paper identified as its primary target.
4
Signal
AMPK activation
It slows the folate cycle and purine synthesis, which switches on the cell's energy sensor.
Exercise link:a 2021 study found that exercise raised MOTS-c in human muscle and blood. That is the body’s own MOTS-c, not an injected product.
Evidence, not marketing.Nov 2026
Mechanism as described in Lee C, et al. Cell Metabolism, 2015 (PubMed 25738459), from cell and mouse experiments. It shows how MOTS-c is thought to work, not a proven benefit in people.
How MOTS-c Works
The 2015 paper reported that MOTS-c's "primary target organ appears to be the skeletal muscle." Inside cells, it slowed the folate cycle and the purine synthesis tied to it. That led to activation of AMPK, an enzyme that senses when a cell is low on energy and shifts it toward burning fuel. The mechanism comes from cell and mouse experiments.
AMPK is the same energy sensor that exercise turns on, which is why MOTS-c is often called an "exercise mimetic." That label is a hypothesis. No human study has shown that injected MOTS-c reproduces the benefits of exercise.
MOTS-c Benefits: What the Evidence Shows
The answer depends on the kind of study.
Cells and mice: consistent. In the 2015 study, MOTS-c treatment in mice "prevented age-dependent and high-fat-diet-induced insulin resistance, as well as diet-induced obesity." A 2021 Nature Communications study from the same research group reported that MOTS-c significantly improved physical performance in young, middle-aged and old mice. Treatment started late in life increased physical capacity and healthspan in the mice. Two authors of that paper disclosed that they were consultants and shareholders of CohBar, the company developing a MOTS-c analog.
People, observational: suggestive. The 2021 study also found that "in humans, exercise induces endogenous MOTS-c expression in skeletal muscle and in circulation." That concerns the body's own MOTS-c. A 2026 systematic review of exercise and mitochondrial-derived peptides found only nine eligible studies. Most showed a rise after exercise, and the authors cautioned that "current evidence is limited, particularly in human studies."
People, controlled trials: not yet. Two trials matter:
CB4211 (NCT03998514). CohBar ran a randomized, placebo-controlled Phase 1a/1b study of this MOTS-c analog in 88 participants, including healthy adults and people with fatty liver disease. It was completed in 2021. Its main goals were safety, tolerability and pharmacokinetics. ClinicalTrials.gov shows no posted results. In its October 2026 policy, HHS describes it as "a randomized placebo-controlled trial of a MOTS-c analogue" that "reported no serious adverse events."
MOTS-c in prediabetes (NCT07505745). A randomized, quadruple-blind, placebo-controlled Phase 2a trial sponsored by Hudson Biotech is testing whether 12 weeks of MOTS-c improves insulin sensitivity in adults with prediabetes and overweight or obesity. It started in February 2026 at a site in Shenzhen, China, plans to enroll 120 people and lists primary completion in February 2027 on ClinicalTrials.gov. No results yet.
So the benefits most often claimed online, such as fat loss, better insulin sensitivity, endurance and healthy aging, are mouse findings that have not been confirmed in people. A 2026 Sports Medicine review of peptides marketed to athletes, MOTS-c among them, put it this way: these peptides show tissue repair and metabolic outcomes "in animal models, but rigorous human safety data are scarce, and there is potential for serious harm to patients."
PeptIQ.io / MOTS-c / 02
Strong in mice. Unproven in people.
Each rung needs better evidence than the one below it. Most claims about MOTS-c benefits come from the bottom two.
FDA-approved drug
None. No company has submitted a MOTS-c drug for approval.
Not reached
Phase 2 trial of MOTS-c
Randomized, placebo-controlled study in adults with prediabetes. 120 planned, primary completion estimated Feb 2027.
Recruiting
Human trial of an analog
CB4211, a MOTS-c analog, completed a Phase 1a/1b safety study in 2021. HHS cites no serious adverse events.
Safety only
Human observational
Exercise tends to raise natural MOTS-c levels, but a 2026 systematic review found only nine studies.
Association
Mice
Less diet-induced obesity and insulin resistance. Better physical capacity in old mice.
Consistent
Cells
Folate cycle, purine synthesis and AMPK activation in muscle cells.
Consistent
Evidence, not marketing.Nov 2026
Sources: Lee 2015 (PubMed 25738459); Reynolds 2021 (PubMed 33473109); Ayubi 2026 systematic review (PubMed 42640735); ClinicalTrials.gov NCT03998514 (no results posted) and NCT07505745; HHS policy Appendix B (October 30, 2026). Checked November 5, 2026.
There is no reliable side-effect profile for MOTS-c in people yet. The placebo-controlled trial that will measure adverse events is still running.
What the record does say:
FDA's concern. When MOTS-c was in category 2, FDA's safety-risk page said compounded MOTS-c "may pose significant risk for immunogenicity" (an unwanted immune reaction) and that FDA "has not identified any human exposure data on drug products containing MOTs-C." That text is still on the page under "nominated but withdrawn."
HHS's view. HHS's October 2026 policy argues that the safety evidence "points in one direction," citing the analog trial and rodent studies that "reported metabolic benefit without systemic toxicity." It also notes that new lot-specific certificates from FDA-registered manufacturers now report the impurity, endotoxin and microbial testing FDA had found missing.
Product quality. Gray-market vials labeled "research use only" are not made for people and are not checked by any regulator. Purity and contamination are unknown unless independently tested.
What about MOTS-c half-life? We did not find a published human pharmacokinetic study of MOTS-c itself. Half-life figures online usually come from animal data or from analogs, and they do not tell you how a given product behaves in your body.
Is MOTS-c FDA Approved or Legal in 2026?
MOTS-c is not FDA approved. No company has submitted a MOTS-c drug for approval.
Its compounding status has moved several times:
September 29, 2023: FDA placed MOTS-c in category 2, its list of bulk substances that may pose significant safety risks.
April 22, 2026: MOTS-c left category 2 after its nominations were withdrawn. HHS notes that "neither the placement nor the removal changed its status under section 503A."
July 23, 2026: FDA's Pharmacy Compounding Advisory Committee (PCAC) reviewed MOTS-c for obesity and osteoporosis, according to the Federal Register meeting notice. HHS reports that FDA staff "recommended against listing either form, and the PCAC voted in favor of both forms." PeptIQ.io covered that split in MOTS-c's 503A recommendation.
October 30, 2026: HHS published an enforcement discretion policy for 503A compounding. MOTS-c is one of six peptides in Appendix A, with BPC-157, epitalon, KPV, Semax and TB-500. For MOTS-c acetate, it covers subcutaneous or intramuscular injectable forms made from an ingredient with a qualifying certificate of analysis.
The conditions are strict. A compounded product has to be made for a patient-specific prescription by a state-licensed pharmacy or physician. It has to use a bulk ingredient from an FDA-registered manufacturer with full lot testing, contain a single peptide rather than a blend, and have serious adverse events reported to FDA's MedWatch. The policy is interim. Public comments on docket HHS-OASH-2026-0496 close November 13, 2026, and FDA still has to finish formal rulemaking on the 503A bulks list.
PeptIQ.io / MOTS-c / 03
Restricted, then reconsidered.
In three years MOTS-c went from FDA’s safety-risk list to an interim compounding policy. None of these steps is FDA approval.
Sep 29, 2023
Placed in category 2
FDA flags possible immune reactions and finds no human exposure data on MOTS-c drug products.
Apr 22, 2026
Out of category 2
Nominations withdrawn. FDA's safety concerns stay on its website.
Jul 23, 2026
Advisory committee votes yes
PCAC favors both forms, reviewed for obesity and osteoporosis. FDA staff had recommended against.
Oct 30, 2026
HHS interim policy
MOTS-c acetate is one of six peptides in Appendix A. Covers injectable forms from registered makers.
Nov 13, 2026
Comments close
Docket HHS-OASH-2026-0496. Formal FDA rulemaking still to come.
Evidence, not marketing.Nov 2026
Sources: FDA safety-risk page for bulk drug substances (current as of April 22, 2026); PCAC meeting notice (Federal Register, April 16, 2026); HHS enforcement discretion policy and Appendix B (Federal Register 2026-22192, October 30, 2026); regulations.gov docket HHS-OASH-2026-0496. Not legal advice.
Telehealth brands already market physician-prescribed MOTS-c programs. One example is motsc.com, a physician-prescribed MOTS-c brand in the meds.you portfolio. Whichever route you look at, compare benefit claims with the human evidence above, and ask which pharmacy compounds the product and whether it meets the HHS conditions.
None of this is legal advice, and state pharmacy rules vary.
Questions to Ask a Clinician
What does the human evidence show for my specific goal, and is there an approved treatment with stronger data?
Is this a compounded drug under the HHS policy, an investigational product in a trial, or a "research use only" chemical?
Which pharmacy makes it, and can I see the certificate of analysis for the lot?
How will we measure whether it is doing anything, for example glucose markers, body composition or exercise capacity?
Which reactions should make me stop and call you, and how do I report them to MedWatch?
How PeptIQ.io Helps
PeptIQ.io's Peptide Claim Auditor takes a link to an Instagram, TikTok, X or Reddit post and checks each peptide claim in it against published research. It is useful for posts calling MOTS-c "proven" or "FDA approved." The COA checker and the COA reading guide explain what a lab report does and does not prove. If you and your clinician decide on a protocol, the PeptIQ app lets you log it alongside symptoms and lab results so you have a record to review together. Community notes live on the MOTS-c wiki page.
Talk to a Licensed Clinician
Talk to a licensed clinician before starting MOTS-c. A primary care clinician or endocrinologist is the right first stop for metabolic goals such as prediabetes or weight. Bring the product name, its label and any certificate of analysis, and report suspected reactions to FDA MedWatch.
Frequently Asked Questions
Q: What is MOTS-c?
A: MOTS-c is a 16-amino-acid peptide encoded in mitochondrial DNA, within the gene for 12S ribosomal RNA. It was described in 2015 and is thought to act mainly on skeletal muscle by activating AMPK, the cell's energy sensor.
Q: What are the benefits of MOTS-c?
A: In mice, MOTS-c reduced diet-induced obesity and insulin resistance and improved physical capacity in old animals. In people, exercise raises natural MOTS-c levels, but no published placebo-controlled trial has shown that taking MOTS-c improves weight, insulin sensitivity or performance.
Q: Is MOTS-c FDA approved?
A: No. No MOTS-c drug has been approved. Since October 30, 2026, an interim HHS policy allows 503A compounding of MOTS-c acetate for individual prescriptions under strict conditions. That is enforcement discretion, not approval.
Q: What are the side effects of MOTS-c?
A: They are not well established in people. FDA has flagged possible immune reactions and a lack of human exposure data. HHS cites an analog trial with no serious adverse events, but those results have not been posted on ClinicalTrials.gov. The ongoing Phase 2a trial is measuring adverse events.
Q: Is there a MOTS-c human trial?
A: Yes. NCT07505745 is a randomized, placebo-controlled Phase 2a trial of MOTS-c in adults with prediabetes and overweight or obesity. It is recruiting, with primary completion estimated for February 2027. An earlier Phase 1 study tested CB4211, a MOTS-c analog.
Q: What is the half-life of MOTS-c?
A: We did not find a published human pharmacokinetic study of MOTS-c itself. Numbers quoted online usually come from animal studies or analogs, so treat them with caution and ask your clinician.
Lee C, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism. 2015. PubMed 25738459
Reynolds JC, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nature Communications. 2021. PubMed 33473109
Ayubi N, et al. Mitochondrial-derived peptides activated by physical exercise as therapeutic targets for metabolic disorders: a systematic review. Physiology International. 2026. PubMed 42640735
Mendias CL, Awan TM. Safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance. Sports Medicine. 2026. PubMed 41966639
This article is educational content from PeptIQ.io. It is not medical advice. Talk with a licensed clinician before starting, stopping, or changing any peptide, medication, or injection practice.
For clinics: running peptide or GLP-1 programs for patients? See PeptIQ.io for providers: protocol templates, a patient app, and adherence tracking in one console.